(MENAFN- iCrowdNewsWire)
The Global Polymer Drug Conjugates Market is estimated exhibit a CAGR of 32.7% during the forecast period.
Request for Sample Pages:
Polymer-drug conjugates are nano-sized pharmaceuticals now employed to treat cancer and hepatitis. Polymers are now being created that are sensitive to certain enzymes found in sick tissue. Conventional polymers, such as cellulose and chitin, can be destroyed by enzymatic activity and acidity in polymer-drug conjugates. The Polymer Drug Conjugates Market is expected to expand rapidly during the forecast period, owing to strong growth in the pharmaceutical industry, particularly in the United States, and heavy investments in medical R&D, which has resulted in the development of technologically advanced medical devices and equipment. Because medical polymers are widely used in the manufacture of pharmaceutical medications, significant growth in the pharmaceutical sector over the last few years has resulted in a rise in demand for medical polymers, which will raise the industry share over the projected period.
List of Prominent Players in the Polymer Drug Conjugates Market:
3S Bio
Abeona Therapeutics
Abramson Cancer Center
Access Pharmaceuticals
Adama
Eyetech
Ferring
Flamel Technologies
Genentech
GlaxoSmithKline
Gowan
Gynecologic Oncology Group Foundation
JenKem Technology
Landec
Lipotek
Curious about this latest version of the report? Obtain Report Details @
Market Dynamics:
Drivers-
New pipeline medications generated using polymer-drug conjugation are likely to drive the polymer-drug conjugates market forward. Government organizations are taking steps to improve the pharmaceutical industry by promoting R&D investment to produce technically advanced equipment that would aid in eradicating fatal diseases in the region. The pressing requirement to produce innovative medical devices would favour the medical polymers' market share over the forecast period. The increased desire of patients for homecare health treatment due to its cost-effectiveness and convenience has increased global demand for medical disposables. This will significantly contribute to achieving a larger market share during the anticipated timeframe.
Challenges:
The polymer-drug conjugates market is predicted to grow slowly due to the limited use of polymer-drug conjugates. The lack of defined and improved preclinical or clinical methodologies for evaluating polymer-drug conjugate stability, tumour penetration, metabolism, and toxicity is impeding market expansion for polymer-drug conjugates. The popularity of minimally invasive operations is growing due to the advantages of these treatments, which include shorter hospital stays, faster recovery times, and minor bleeding and pain. The increased preference for these procedures over traditional surgery has curtailed the usage of specific medical equipment, potentially impeding the market growth. The cost and time required for a product to enter the clinical trial stage and then pass the clinical trials are prohibitively expensive, with little possibility of approval. Furthermore, the ability to gather clinically meaningful data demonstrating clinical trial clearance has been crucial for such devices. This is a major problem restricting the market development of innovative Polymer Drug Conjugates.
Regional Trends:
Due to the rising number of clinical studies taking place in the United States, North America is predicted to lead the global market for polymer-drug conjugates. The fast expansion of the pharmaceutical industries in Mexico and Canada, as well as the increased need for medical polymers in pharmaceutical medications, are projected to fuel additional growth. The need for medical devices has risen as a result of the region's ageing population growth and the prevalence of chronic illnesses. As more equipment is made, this will probably increase the demand for medical polymers throughout the projected period. For the forecast period, rising government investments in the healthcare industry and the home healthcare market are projected to boost demand for medical equipment, which would benefit the polymer drug conjugates market.
Recent Developments:
- In September 2020, DSM announced a collaboration with PBC Biomed, an Irish medical device design and development firm. This collaboration will first concentrate on developing regenerating bone adhesives for safe and cost-effective surgical operations.
- In September 2020, Corbion and Total announced plans to develop a new PLA medical polymer plant in Europe under their Total Corbion PLA joint venture. The plant, which will be Europe's first global-scale PLA production facility, is estimated to have a capacity of 100,000 tonnes per year. This additional PLA investment will hasten plans to increase lactic acid production.
Segmentation of Polymer Drug Conjugates Market-
By Product Type
- Polymer-Dox Conjugates
- Polymer-Paclitaxel Conjugates
- Polymer-Camptothecin Conjugates
- Polymer-Platinate Conjugates
By Application
- Cancer Treatment
- Leukemia
- Hepatitis
- Others
By Region-
North America-
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
For More Information @
MENAFN06102022003318003403ID1104977293
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.